{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:18:27Z","timestamp":1780579107108,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2026.102506","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:16:01Z","timestamp":1768436161000},"page":"102506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1530-7252","authenticated-orcid":false,"given":"Alia","family":"Harba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-5220","authenticated-orcid":false,"given":"Fabien","family":"Moinard-Butot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-4840","authenticated-orcid":false,"given":"Edouard","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-5023","authenticated-orcid":false,"given":"Johanna","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-3571","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-0845","authenticated-orcid":false,"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Jaffrelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostefa","family":"Bennamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Roulleaux-Dugage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-214X","authenticated-orcid":false,"given":"Mathilde","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-1117","authenticated-orcid":false,"given":"Victor","family":"Heurtier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0740-1120","authenticated-orcid":false,"given":"Hamid","family":"Lardjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0893-285X","authenticated-orcid":false,"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1341","authenticated-orcid":false,"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2026.102506_bib0001","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102506_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.clgc.2026.102506_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.clgc.2026.102506_bib0004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.clgc.2026.102506_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/annonc\/mdq342","article-title":"Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma","volume":"22","author":"Patil","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102506_bib0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102506_bib0007","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1038\/bjc.2013.236","article-title":"Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma","volume":"108","author":"Motzer","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102506_bib0008","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102506_bib0009","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102506_bib0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2022.12.028","article-title":"Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: results of the GETUG-AFU26-NIVOREN multicentre phase II study","volume":"182","author":"Velev","year":"2023","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.clgc.2026.102506_bib0011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2026.102506_bib0012","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2026.102506_bib0013","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102506_bib0014","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102506_bib0015","unstructured":"ASCO 2025: Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final Analysis from the phase 3 CheckMate 214 trial. Accessed: August 9, 2025 Available at: https:\/\/www.urotoday.com\/conference-highlights\/asco-2025\/asco-2025-kidney-cancer\/160902-asco-2025-nivolumab-plus-ipilimumab-vs-sunitinib-for-first-line-treatment-of-advanced-renal-cell-carcinoma-final-analysis-from-the-phase-3-checkmate-214-trial.html."},{"key":"10.1016\/j.clgc.2026.102506_bib0016","unstructured":"ASCO GU 2025: Nivolumab plus cabozantinib vs sunitinib for previously untreated advanced renal cell carcinoma: final follow-up results from the CheckMate 9ER trial. Accessed: July 10, 2025 Available at: https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2025\/asco-gu-2025-kidney-cancer\/158352-asco-gu-2025-nivolumab-plus-cabozantinib-n-c-vs-sunitinib-s-for-previously-untreated-advanced-renal-cell-carcinoma-arcc-final-follow-up-results-from-the-checkmate-9er-trial.html."},{"issue":"7","key":"10.1016\/j.clgc.2026.102506_bib0017","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102506_bib0018","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2026.102506_bib0019","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2026.102506_bib0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"40","key":"10.1016\/j.clgc.2026.102506_bib0021","doi-asserted-by":"crossref","first-page":"68890","DOI":"10.18632\/oncotarget.20323","article-title":"Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"8","author":"Omae","year":"2017","journal-title":"Oncotarget"},{"issue":"0","key":"10.1016\/j.clgc.2026.102506_bib0022","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2020","volume":"0","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102506_bib0023","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1016\/S0007-4551(18)30382-5","article-title":"Traitement des m\u00e9tastases osseuses du cancer du rein","volume":"105","author":"Guida","year":"2018","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.clgc.2026.102506_bib0024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102506_bib0025","article-title":"Treatment outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study","volume":"22","author":"Buti","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.clgc.2026.102506_bib0026","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1111\/cas.14902","article-title":"Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases","volume":"112","author":"Kato","year":"2021","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.clgc.2026.102506_bib0027","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11523-021-00832-3","article-title":"A multi-institutional, retrospective analysis of patients with metastatic renal cell carcinoma to bone treated with combination ipilimumab and nivolumab","volume":"16","author":"Desai","year":"2021","journal-title":"Target Oncol"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2026.102506_bib0028","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2025.43.5_suppl.490","article-title":"Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): a contemporary national real-world analysis","volume":"43","author":"Millan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102506_bib0029","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"34","key":"10.1016\/j.clgc.2026.102506_bib0030","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102506_bib0031","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102506_bib0032","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.clgc.2026.102506_bib0033","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","article-title":"Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions","volume":"20","author":"Dai","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.clgc.2026.102506_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078881","article-title":"Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling","volume":"8","author":"Nguyen","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.clgc.2026.102506_bib0035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bone.2015.08.003","article-title":"Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo","volume":"81","author":"Haider","year":"2015","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.clgc.2026.102506_bib0036","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:28:49Z","timestamp":1771705729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767326000066"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102506","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102506"}}